Bought a first position here. I like the risk/reward ratio… Price: $1.02 Market Cap: ~ $6.4 Million Shares Outstanding: ~ 6.3 Million Cash balance (as of March 31, 2020): ~ $9.4 Million Cash expected to fund through mid 2021 Lead product: XCART™ (Preclinical, see slide 24 for possible value of CAR T therapeutics acquisitions with lead program in preclinical development) Company presentation July 2020 https://ir.xeneticbio.com/presentations
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology Wed, December 9, 2020, 2:35 PM GMT Xenetic leverages its proprietary drug delivery platform, PolyXen, through partnerships with biotechnology and pharmaceutical companies to improve the half-life and other pharmacological properties of next-generation biologic drugs Epolong, a polysialylated form of recombinant human erythropoietin that leverages PolyXen, has been shown to be effective and generally well tolerated in Pharmsynthez-conducted trial as a treatment for anemia in patients with chronic kidney disease
